Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (380) 380
Patent (72) 72
Conference Proceeding (40) 40
Publication (16) 16
Book Chapter (6) 6
Book Review (3) 3
Book / eBook (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (181) 181
oncology (162) 162
index medicus (135) 135
female (108) 108
cancer (76) 76
breast cancer (73) 73
aged (71) 71
middle aged (70) 70
electric communication technique (67) 67
electricity (67) 67
antineoplastic agents - therapeutic use (66) 66
wireless communications networks (63) 63
adult (62) 62
chemotherapy (60) 60
breast neoplasms - drug therapy (57) 57
male (52) 52
neoplasms - drug therapy (48) 48
hematology, oncology and palliative medicine (44) 44
metastasis (43) 43
treatment outcome (42) 42
care and treatment (39) 39
antineoplastic agents - adverse effects (33) 33
pharmacology & pharmacy (33) 33
research (33) 33
tumors (32) 32
breast neoplasms - pathology (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
solid tumors (29) 29
medicine & public health (27) 27
aged, 80 and over (24) 24
clinical trials (23) 23
clinical trials as topic (23) 23
survival (23) 23
analysis (22) 22
dose-response relationship, drug (22) 22
melanoma (22) 22
prognosis (22) 22
antineoplastic agents (21) 21
combination (20) 20
trial (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
drug administration schedule (19) 19
hematology (19) 19
paclitaxel (19) 19
trastuzumab (19) 19
antineoplastic agents - administration & dosage (18) 18
cancer therapies (18) 18
disease-free survival (18) 18
pharmacokinetics (18) 18
therapy (18) 18
antimitotic agents (17) 17
drug therapy (17) 17
interference (17) 17
oncology, experimental (17) 17
pharmacology/toxicology (17) 17
receptor, erbb-2 - metabolism (17) 17
toxicity (17) 17
transmission (17) 17
cancer research (16) 16
immunotherapy (16) 16
neoplasm metastasis (16) 16
phase-ii trial (16) 16
phase-iii trial (16) 16
antineoplastic agents - pharmacology (15) 15
antineoplastic combined chemotherapy protocols - pharmacokinetics (15) 15
breast neoplasms - metabolism (15) 15
cell lung-cancer (15) 15
expression (15) 15
metastatic breast cancer (15) 15
safety (15) 15
survival analysis (15) 15
animals (14) 14
molecular targeted therapy (14) 14
neoplasm staging (14) 14
neoplasms - pathology (14) 14
combined modality therapy (13) 13
docetaxel (13) 13
dosage and administration (13) 13
resistance (13) 13
signal to noise ratio (13) 13
sorafenib (13) 13
anthracyclines (12) 12
carcinoma (12) 12
health aspects (12) 12
metastatic breast-cancer (12) 12
open-label (12) 12
optimization (12) 12
patients (12) 12
protein kinase inhibitors - therapeutic use (12) 12
review (12) 12
tyrosine kinase inhibitor (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
antitumor-activity (11) 11
breast neoplasms - genetics (11) 11
breast neoplasms - mortality (11) 11
capecitabine (11) 11
drug delivery systems (11) 11
drug resistance, neoplasm (11) 11
endothelial growth-factor (11) 11
maximum tolerated dose (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cisplatin/Epinephrine Injectable Gel: A Viewpoint by Ahmad Awada
by Awada A
Drugs & Aging, ISSN 1170-229X, 10/2001, Volume 18, Issue 10, pp. 794 - 795
New drug profiles | Antineoplastics, general | MPI 5010, general | Solid tumours, treatment | Elderly | Research and development | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives
by Kotecki, Nuria and Awada, Ahmad
Current Opinion in Oncology, ISSN 1040-8746, 09/2019, Volume 31, Issue 5, pp. 439 - 444
PURPOSE OF REVIEWThe aim of this review is to provide an overview of the current development of immuno-oncology in the (neo)adjuvant setting. RECENT... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
by Baselga, José, Prof and Im, Seock-Ah, Prof and Iwata, Hiroji, MD and Cortés, Javier, MD and De Laurentiis, Michele, MD and Jiang, Zefei, Prof and Arteaga, Carlos L, Prof and Jonat, Walter, Prof and Clemons, Mark, Prof and Ito, Yoshinori, MD and Awada, Ahmad, Prof and Chia, Stephen, MD and Jagiełło-Gruszfeld, Agnieszka, MD and Pistilli, Barbara, MD and Tseng, Ling-Ming, MD and Hurvitz, Sara, MD and Masuda, Norikazu, MD and Takahashi, Masato, MD and Vuylsteke, Peter, MD and Hachemi, Soulef, PhD and Dharan, Bharani, MS and Di Tomaso, Emmanuelle, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Campone, Mario, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
by Leboulleux, Sophie, MD and Bastholt, Lars, MD and Krause, Thomas, Prof and de la Fouchardiere, Christelle, MD and Tennvall, Jan, Prof and Awada, Ahmad, Prof and Gómez, José Manuel, MD and Bonichon, Françoise, MD and Leenhardt, Laurence, Prof and Soufflet, Christine, MD and Licour, Muriel, MSc and Schlumberger, Martin J, Prof and Onkologi och Patologi, MV and Lund University and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Oncology and Pathology, MV and Lunds universitet
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 897 - 905
Summary Background No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to... 
Hematology, Oncology and Palliative Medicine | CRITERIA | MALIGNANT-TUMORS | SOLID TUMORS | ONCOLOGY | PAPILLARY | SORAFENIB | INHIBITOR | CARCINOMA | ZD6474 | Carcinoma | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Young Adult | Lung Neoplasms - secondary | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | ErbB Receptors - antagonists & inhibitors | Thyroid Neoplasms - mortality | Double-Blind Method | Kaplan-Meier Estimate | Electrocardiography - drug effects | Heart Conduction System - drug effects | Lymphatic Metastasis | Thyroid Cancer, Papillary | Disease-Free Survival | Adenocarcinoma, Follicular | Thyroid Neoplasms - drug therapy | Carcinoma, Papillary | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Adolescent | Quinazolines - adverse effects | Skin Neoplasms - secondary | Survival Analysis | Thyroid Neoplasms - secondary | Aged | Thyroid Neoplasms - pathology | Tyrosine | Care and treatment | Thyroid cancer | Clinical trials | Product development | Metastasis | Vascular endothelial growth factor | Cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text PRIMA-1 and PRIMA-1Met (APR-246): From mutant/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies
by Perdrix, Anne and Najem, Ahmad and Saussez, Sven and Awada, Ahmad and Journe, Fabrice and Ghanem, Ghanem and Krayem, Mohammad
Cancers, ISSN 2072-6694, 12/2017, Volume 9, Issue 12, p. 172
p53 protects cells from genetic assaults by triggering cell-cycle arrest and apoptosis. Inactivation of p53 pathway is found in the vast majority of human... 
P53 reactivation | Drug combination | APR-246 | PRIMA-1 | Cancer | P53 | Proteins | Missense mutation | Developmental stages | p53 Protein | Clinical trials | Mutation | Cancer therapies | Apoptosis | Tumors | Life Sciences | p53 reactivation | drug combination | cancer | PRIMA-1Met | p53
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Meet our editorial board member
by Awada, Ahmad
Current Clinical Pharmacology, ISSN 1574-8847, 2015, Volume 10, Issue 4, p. 253
Journal Article
Details down arrow
7. Full Text Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials
by Takimoto, Chris H and Takimoto, Chris H and Awada, Ahmad and Awada, Ahmad
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2008, Volume 61, Issue 4, pp. 535 - 548
Sorafenib (Nexavar®) is an oral multi-kinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases involved in tumor growth and... 
Chemotherapy | Biomedicine | Combination | Sorafenib | Phase I/II clinical trials | Oncology | Cancer Research | Targeted agent | Solid tumors | Pharmacology/Toxicology | phase I/II | ADVANCED SOLID TUMORS | BAY-43-9006 | sorafenib | MALIGNANT-MELANOMA | chemotherapy | solid tumors | RENAL-CELL CARCINOMA | METASTATIC MELANOMA | LUNG-CANCER | ONCOLOGY | PHASE-I TRIAL | THERAPEUTIC TARGET | PHARMACOLOGY & PHARMACY | clinical trials | B-RAF | targeted agent | combination | RAF ANTISENSE OLIGONUCLEOTIDE | Niacinamide - analogs & derivatives | Humans | Pyridines - pharmacokinetics | Clinical Trials as Topic | Phenylurea Compounds | Antineoplastic Agents - toxicity | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antineoplastic Combined Chemotherapy Protocols - toxicity | Benzenesulfonates - adverse effects | Neoplasms - drug therapy | Benzenesulfonates - pharmacokinetics | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Animals | Drug Interactions | Pyridines - toxicity | Antineoplastic Agents - adverse effects | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Pyridines - pharmacology | Benzenesulfonates - toxicity | Antimitotic agents | Clinical trials | Care and treatment | Antineoplastic agents | Protein kinases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
by Twelves, Chris and Cortes, Javier and Vahdat, Linda and Olivo, Martin and He, Yi and Kaufman, Peter A and Awada, Ahmad
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2014, Volume 148, Issue 3, pp. 553 - 561
Data from two phase 3 studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient... 
Oncology | Metastatic breast cancer | Medicine & Public Health | Pooled analysis | Eribulin mesylate | Halaven | ONCOLOGY | SAFETY | DOXORUBICIN | FOLLOW-UP | PATTERNS | DOCETAXEL | CHEMOTHERAPY | RECHALLENGE | Anthracyclines - adverse effects | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Furans - adverse effects | Neoplasm Metastasis | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Ketones - adverse effects | Taxoids - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Ketones - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Aged | Bridged-Ring Compounds - administration & dosage | Deoxycytidine - analogs & derivatives | Furans - administration & dosage | Women | Care and treatment | Anthracyclines | Chemotherapy | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Cancer | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
by Harold J. Burstein and Yan Sun and Luc Y. Dirix and Zefei Jiang and Robert Paridaens and Antoinette R. Tan and Ahmad Awada and Anantbhushan Ranade and Shunchang Jiao and Gary Schwartz and Richat Abbas and Christine Powell and Kathleen Turnbull and Jennifer Vermette and Charles Zacharchuk and Rajendra Badwe
Journal of Clinical Oncology, ISSN 0732-183X, 03/2010, Volume 28, Issue 8, pp. 1301 - 1307
Purpose Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The efficacy and safety of neratinib were evaluated in two cohorts of... 
ADJUVANT CHEMOTHERAPY | SINGLE-AGENT | SOLID TUMORS | TRASTUZUMAB | EFFICACY | ONCOLOGY | SAFETY | PHASE-II | LAPATINIB MONOTHERAPY | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Drug-Related Side Effects and Adverse Reactions | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Administration, Oral | Breast Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Quinolines - therapeutic use | Quinolines - adverse effects | Trastuzumab | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
by Perez, Edith A, Dr and Awada, Ahmad, MD and O'Shaughnessy, Joyce, MD and Rugo, Hope S, MD and Twelves, Chris, MD and Im, Seock-Ah, MD and Gómez-Pardo, Patricia, MD and Schwartzberg, Lee S, MD and Diéras, Veronique, MD and Yardley, Denise A, MD and Potter, David A, MD and Mailliez, Audrey, MD and Moreno-Aspitia, Alvaro, MD and Ahn, Jin-Seok, MD and Zhao, Carol, MS and Hoch, Ute, PhD and Tagliaferri, Mary, MD and Hannah, Alison L, MD and Cortes, Javier, MD
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1556 - 1568
Summary Background New options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | RESISTANT | IXABEPILONE PLUS CAPECITABINE | PHARMACOKINETICS | ONCOLOGY | Bridged-Ring Compounds - therapeutic use | Physicians | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Antibiotics, Antineoplastic | Capecitabine - therapeutic use | Breast Neoplasms - drug therapy | Polyethylene Glycols - therapeutic use | Taxoids - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Medical colleges | Care and treatment | Anthracyclines | Breast cancer | Product development | Metabolites
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
by Krayem, M and Sabbah, M and Najem, A and Wouters, A and Lardon, F and Simon, S and Sales, F and Journe, F and Awada, A and Ghanem, GE and Van Gestel, D
CANCERS, ISSN 2072-6694, 08/2019, Volume 11, Issue 8, p. 1093
Radiotherapy (RT) in patients with melanoma historically showed suboptimal results, because the disease is often radioresistant due to various mechanisms such... 
ACTIVATION | CANCER CELLS | p53 activation | melanoma | COMBINATION | (V600E)BRAF inhibition | RADIATION-THERAPY | BRAF INHIBITOR | ONCOLOGY | IN-VIVO | radiotherapy | RESISTANCE | TARGETING P53 | SKIN | intrinsic and acquired resistance | VEMURAFENIB | V600EBRAF inhibition
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
by José Baselga and Patricia Gómez and Richard Greil and Sofia Braga and Miguel A. Climent and Andrew M. Wardley and Bella Kaufman and Salomon M. Stemmer and António Pêgo and Arlene Chan and Jean-Charles Goeminne and Marie-Pascale Graas and M. John Kennedy and Eva Maria Ciruelos Gil and Andreas Schneeweiss and Angela Zubel and Jutta Groos and Helena Melezínková and Ahmad Awada
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 20, pp. 2586 - 2592
Purpose Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our... 
TRIAL | MULTICENTER | EFFICACY | ONCOLOGY | SUBTYPES | COLORECTAL-CANCER | PLATINUM-BASED CHEMOTHERAPY | OXALIPLATIN | COMBINATION | EXPRESSION | CARCINOMA | Multivariate Analysis | Confidence Intervals | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Cisplatin - administration & dosage | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Invasiveness - pathology | Adult | Female | Cetuximab | Antibodies, Monoclonal, Humanized - adverse effects | ErbB Receptors - metabolism | Drug Administration Schedule | Risk Assessment | Proportional Hazards Models | Treatment Outcome | ErbB Receptors - drug effects | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Receptors, Estrogen - drug effects | Breast Neoplasms - pathology | Receptors, Progesterone - drug effects | Survival Analysis | Cisplatin - adverse effects | Breast Neoplasms - mortality | Aged | Neoplasm Staging | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text New drug combination strategies in melanoma: Current status and future directions
by Najem, Ahmad and Krayem, Mohammad and Perdrix, Anne and Kerger, Joseph and Awada, Ahmad and Journe, Fabrice and Ghanem, Ghanem
Anticancer Research, ISSN 0250-7005, 11/2017, Volume 37, Issue 11, pp. 5941 - 5953
Melanoma is the deadliest form of skin cancer and one of the most difficult cancers to treat. Overall, melanomas have more mutations than any other cancer... 
Targeted therapies | Immunotherapy | Review | Drug resistance | MAPK | Radiotherapy | p53 | WILD-TYPE P53 | targeted therapies | IMPROVED SURVIVAL | RADIATION-THERAPY | METASTATIC MELANOMA | LUNG-CANCER | MEK INHIBITION | ONCOLOGY | SIGNALING PATHWAY | review | immunotherapy | radiotherapy | MUTANT P53 | BRAF INHIBITOR RESISTANCE | drug resistance | COLORECTAL-CANCER CELLS | Drugs, Investigational - therapeutic use | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Melanoma - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
by Vermorken, Jan B and Remenar, Eva and van Herpen, Carla and Gorlia, Thierry and Mesia, Ricard and Degardin, Marian and Stewart, John S and Jelic, Svetislav and Betka, Jan and Preiss, Joachim H and van den Weyngaert, Danielle and Awada, Ahmad and Cupissol, Didier and Kienzer, Heinz R and Rey, Augustin and Desaunois, Isabelle and Bernier, Jacques and Lefebvre, Jean-Louis and EORTC 24971 TAX 323 Stu and EORTC 24971/TAX 323 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 10/2007, Volume 357, Issue 17, pp. 1695 - 1704
This trial of therapies for unresectable advanced head and neck cancer showed that induction chemotherapy (given before radiotherapy) with a combination of... 
PHASE-III TRIAL | SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | METAANALYSIS | NEOADJUVANT CHEMOTHERAPY | INDUCTION CHEMOTHERAPY | SQUAMOUS-CELL CARCINOMA | ACCELERATED RADIOTHERAPY | CHEMORADIOTHERAPY | LOCALLY ADVANCED HEAD | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Squamous Cell - surgery | Male | Combined Modality Therapy | Radiotherapy - adverse effects | Carcinoma, Squamous Cell - radiotherapy | Cisplatin - administration & dosage | Disease-Free Survival | Head and Neck Neoplasms - radiotherapy | Taxoids - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Neoplasm Staging | Head and Neck Neoplasms - surgery | Chemotherapy | Squamous cell carcinoma | Docetaxel | Dosage and administration | Research | Drug therapy, Combination | Comparative analysis | Drug therapy | Cisplatin | Fluorouracil | Cancer | Radiation therapy | Head & neck cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
by Krayem, Mohammad and Journe, Fabrice and Wiedig, Murielle and Morandini, Renato and Najem, Ahmad and Salès, François and van Kempen, Leon C and Sibille, Catherine and Awada, Ahmad and Marine, Jean-Christophe and Ghanem, Ghanem
European Journal of Cancer, ISSN 0959-8049, 03/2016, Volume 55, pp. 98 - 110
Intrinsic and acquired resistance of metastatic melanoma to BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway,... 
Vemurafenib | PRIMA-1Met | Drug resistance | V600E/KBRAF | Melanoma | p53 | BRAF | PRIMA-1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study
by Kaufman, Bella, Dr and Trudeau, Maureen, Prof and Awada, Ahmad, Prof and Blackwell, Kimberly, MD and Bachelot, Thomas, MD and Salazar, Vanessa, BS and DeSilvio, Michelle, PhD and Westlund, Ronald, MS and Zaks, Tal, MD and Spector, Neil, MD and Johnston, Stephen, MD
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 6, pp. 581 - 588
Summary Background Inflammatory breast cancer is an aggressive and biologically distinct form with a higher frequency of HER2 overexpression than other breast... 
Hematology, Oncology and Palliative Medicine | ACTIVATION | THERAPY | TRASTUZUMAB | ONCOLOGY | HERCEPTIN | GROWTH | PROGRESS | RESISTANCE | TYROSINE KINASE INHIBITOR | ANTITUMOR-ACTIVITY | CARCINOMA | Recurrence | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Antineoplastic Agents - therapeutic use | Skin Diseases - pathology | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Breast Neoplasms - genetics | Quinazolines - therapeutic use | Adult | Breast Neoplasms - mortality | Female | Aged | Tyrosine | Care and treatment | Anthracyclines | Growth | Oncology, Experimental | Patient outcomes | Breast cancer | Research | Epidermal growth factor | Enzyme inhibitors | Analysis | Phosphotransferases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights